Benitec Biopharma Inc (NASDAQ: BNTC) is a clinical-stage biopharmaceutical company developing gene-silencing therapies based on its DNA-directed RNA interference (ddRNAi) and silence-and-replace platform technologies. The company generates no product revenue; it is funded entirely through equity raises, including a $30.5 million financing completed March 25, 2025, and an at-the-market offering facility of up to $75 million entered into October 11, 2024. As of June 30, 2025, BNTC held approximately $97.7 million in cash and cash equivalents. Total expenses for the fiscal year ended June 30, 2025 were $41.8 million, comprising $18.3 million in research and development and $23.4 million in general and administrative costs. The company confirmed it did not generate or recognize any revenue during the fiscal years ended June 30, 2025 or June 30, 2024. BNTC operates as a pre-revenue entity competing in the gene therapy space against other developers of RNA interference and gene-editing therapeutics.

Revenue model

No product revenue generated as of fiscal year ended June 30, 2025 or June 30, 2024. The company is funded through equity issuances, including at-the-market offerings and direct financings. Future revenue, if any, would come from product sales upon regulatory approval, or from out-licensing, collaboration milestones, and royalties on licensed intellectual property.

Products and services

ddRNAi (DNA-directed RNA interference) platform for gene silencing; silence-and-replace product candidates designed to permanently silence disease-causing genes while simultaneously restoring wild-type gene function via a single administration using modified viral vectors. Programs target chronic diseases, including indications that may qualify for orphan drug designation.

Customers and end markets

No commercial customers as of fiscal year ended June 30, 2025. End markets are patients with chronic diseases, including rare disease indications eligible for orphan drug designation in the United States and European Union. Future sales would depend on coverage by third-party payers including federal and state government healthcare programs, commercial insurers, and managed care organizations.

Value-chain role

Early-stage drug developer and IP licensor. The company licenses intellectual property from third parties and may out-license its ddRNAi technology to collaborators. Manufacturing is conducted through third-party contract manufacturers.

Geographic exposure

Incorporated in the United States; subsidiary Benitec Biopharma Limited (BBL) operates with Australian dollar (AUD) as functional currency, indicating Australian operations. Reporting currency is the United States dollar.

Source: SEC 10-K, filed 2025-09-22

Industry: Pharmaceutical Preparations Peers: Acorda Therapeutics, Inc. Cibus Inc Sonnet BioTherapeutics Holdings, Inc. Statera Biopharma, Inc. Ensysce Biosciences Inc Exicure Inc Xenetic Biosciences Inc NAVIDEA BIOPHARMACEUTICALS, INC. Phio Pharmaceuticals Corp